Form 4: Haemonetics Director Michael Coyle Awarded Restricted Stock Units

Haemonetics Corporation's Director, Michael J. Coyle, was granted 2,693 restricted stock units, aligning his interests with shareholders.

Summary

• Director Michael J. Coyle of Haemonetics Corp (HAE) was granted 2,693 shares of common stock in the form of Restricted Stock Units (RSUs) on July 24, 2025.
• The RSUs were issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• These RSUs are scheduled to vest 100% on the first anniversary of the grant date, which is July 24, 2026.
• Following this transaction, Mr. Coyle's direct beneficial ownership of Haemonetics common stock will be 15,394 shares.

Sentiment

Score: 8

Explanation: The grant of restricted stock units to a director is a positive signal, as it aligns the director's financial interests with the long-term performance of the company and its shareholders.

Positives

• The grant of Restricted Stock Units to Director Michael J. Coyle aligns his financial interests with those of the company's shareholders.
• The award is part of a long-term incentive compensation plan, indicating a commitment to retaining and incentivizing key personnel.

Risks

• The value of the restricted stock units is subject to the future performance of Haemonetics Corporation's common stock.

Future Outlook

The grant of long-term incentive compensation suggests a continued focus on aligning management and director interests with the company's long-term performance.

Industry Context

The use of Restricted Stock Units (RSUs) as a form of executive and director compensation is a common practice across various industries, including the medical technology and healthcare sectors, to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The grant of RSUs to a director is a standard practice in corporate governance, comparable to compensation structures seen in other medical technology companies like Medtronic (MDT) or Abbott Laboratories (ABT), which frequently use equity awards to compensate their board members and executives.
• The vesting schedule of 100% on the first anniversary is a common short-to-medium term vesting period for director equity grants, aiming to retain directors and align their interests over a reasonable timeframe.

Stakeholder Impact

• Shareholders: Interests are better aligned with the director due to equity ownership.
• Management/Directors: Compensation structure reinforces long-term commitment to company performance.

Next Steps

• The granted RSUs are expected to vest on July 24, 2026.

Key Dates

Recommendation

The filing reports a standard equity grant to a director, which is a positive signal of alignment between management and shareholder interests. However, this single transaction alone does not provide sufficient fundamental information to warrant a 'buy' or 'sell' recommendation, thus a 'hold' stance is appropriate, pending further financial and strategic updates.

Keywords

Haemonetics, HAE, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Form 4, Michael J. Coyle